5751-83-7

Usage

Uses

Used in Organic Synthesis:
Ethyl 5-bromothiophene-2-carboxylate is used as an intermediate for [application reason] in the field of organic chemistry. Its unique chemical structure allows it to be a valuable component in the synthesis of various complex organic molecules, contributing to the development of new pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Ethyl 5-bromothiophene-2-carboxylate is used as a key intermediate for [application reason] the development of novel drugs. Its incorporation into drug candidates can potentially enhance their therapeutic properties, such as improving bioavailability, selectivity, and efficacy.
Used in Agrochemical Industry:
Ethyl 5-bromothiophene-2-carboxylate is also utilized as a building block in the agrochemical industry for [application reason] the creation of new pesticides and other crop protection agents. Its integration into these products can lead to more effective and targeted pest control solutions, ultimately benefiting agricultural productivity and sustainability.
Used in Specialty Chemicals:
In the specialty chemicals sector, Ethyl 5-bromothiophene-2-carboxylate is employed as a versatile intermediate for [application reason] the production of various high-value chemicals. These can include dyes, additives, and other functional materials that find applications in a wide range of industries, from textiles to electronics.

InChI:InChI=1/C7H7BrO2S/c1-2-10-7(9)5-3-4-6(8)11-5/h3-4H,2H2,1H3

Upstream product

• 2810-04-0 Ethyl thiophene-2-carboxylate 
• 128-08-5 N-Bromosuccinimide 
• 3141-27-3 2,5-dibromothiophen 
• 623-49-4 ethyl cyanoformate 
• 7311-63-9 5-bromothiophene-2-carboxylic acid 
• 64-17-5 ethanol 
• 4701-17-1 5-bromo-2-thiophencarboxaldehyde 
• 5370-25-2 2-Acetyl-5-bromothiophene 
• 75-03-6 ethyl iodide 
• 1003-09-4 2-bromothiophene 
• 56-23-5 tetrachloromethane 
• 1609-47-8 diethyl dicarbonate 
• 31555-60-9 5-bromothiophene-2-carbonyl chloride 

Downstream Products

• 98027-27-1 5-bromo-thiophene-2-carboxylic acid hydrazide 
• 7311-63-9 5-bromothiophene-2-carboxylic acid 
• 31555-60-9 5-bromothiophene-2-carbonyl chloride 
• 13858-71-4 ethyl 5-(4-methoxyphenyl) thiophene-2-carboxylate 
• 1035271-35-2 ethyl 5-(4-methyl-1,4-diazepan-1-yl)thiophene-2-carboxylate 
• 1022905-49-2 C₂₁H₁₉ClO₃S 
• 1132825-49-0 5-[2-methyl-5-(4-morpholin-4-yl-phenylcarbamoyl)-phenyl]-thiophene-2-carboxylic acid ethyl ester 
• 1130165-77-3 ethyl 5-(4-octylphenyl)-2-thiophenecarboxylate 
• 1263098-96-9 5-(3,3-dimethylbut-1-ynyl)-3-iodothiophene-2-carboxylic acid 
• 1263098-97-0 methyl 5-(3,3-dimethylbut-1-ynyl)-3-iodothiophene-2-carboxylate 
• 1315470-92-8 5-(3,3-dimethyl-but-1-ynyl)-3-[(trans-4-methyl-cyclohexanecarbonyl)-pyrrolidin-3-(S)-yl-amino]-thiophene-carboxylic acid methyl ester 

Relevant academic research and scientific papers

New iridium-containing conjugated polymers for polymer solar cell applications

A series of novel donor-acceptor (D-A) copolymers P1-P5 with iridium-complexed moieties in their side chains have been synthesized on the basis of a new iridium-containing monomer. The results obtained show that P1-P5 have good thermal stability (317-347 °C) for photovoltaic applications. These copolymers absorb visible light in a broad spectral range up to 680 nm. The optical bandgaps of P1-P5 are in the range of 1.96-2.08 eV, respectively. The HOMO and LUMO energy levels of the polymers P1-P5 estimated from cyclic voltammetry measurements indicate that these copolymers are suitable as electron donors along with PC71BM as an electron acceptor for bulk heterojunction polymer solar cells. BHJ polymer solar cells were developed based on blend compositions (P1-P5):PC71BM. The values of Jsc, Voc, and FF are in the range of 0.95-4.44 mA cm?2, 0.67-0.69 V and 34.6-56.8%, and the power conversion efficiencies (PCE) are in the range of 0.22-1.74%, respectively, the highest value of 1.74% being for P3. Increase of the photovoltaic parameters was achieved with increasing iridium complex percentage in the polymers due to involvement of triplet effects. The improvement in the efficiency of the triplet-forming polymers P2 and P3 in comparison with P1 appears to be due to the formation of triplet excitons in comparison with singlet excitons in the polymer P1 which does not contain heavy metals. With further increase in the content of iridium complex fragments in the polymers, for example, up to 3 mol% for polymer P4, the efficiency falls to 1.23% and further decreased to 0.22% for P5.

Regiocontrolled Halogen Dance of Bromothiophenes and Bromofurans

The LDA (lithium diisopropylamide)-promoted regiocontrolled halogen dance of α-bromothiophenes and α-bromofurans is described. Bromothiophenes bearing a diethyl acetal moiety undergo selective deprotonation at the β-position adjacent to the bromo group. In contrast, oxazoline, ester, and amide groups act as directing groups in the initial lithiation step to generate a carbanion at the β-position neighboring the directing group to exclusively give the other regioisomer. These results can be applied to the regiocontrolled halogen dance of bromofuran derivatives.

Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease

We have identified chemical probes that act as dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors (>1 log unit difference versus class I HDACs) to decipher the contribution of HDAC isoforms to the positive impact of dua

HETEROCYCLIC DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C

Use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in treating or alleviating HCV, formula (I): wherein R1, R2, R4, Y1, Y2, Y3, A, B and W are as defined in the specification.

Synthesis of 2-thiophenecarboxylic and 2,5-thiophenedicarboxylic acid esters via the reaction of thiophenes with the CCl4-ROH reagent in the presence of vanadium, iron, and molybdenum catalysts

2-Thiophenecarboxylic and 2,5-thiohenedicarboxylic acid esters were synthesized via the reaction of thiophene with the CCl4-ROH-catalyst system, with a total yield of 44-85%. A possible reaction scheme includes the successive steps of alkylation of thiophene with carbon tetrachloride, leading to 2-trichloromethylthiophene, and alcoholysis of the product giving the corresponding 2-thiophenecarboxylate. The best catalysts for this reaction are VO(acac)2, Fe(acac)3, and Mo(CO)6.

Direct conversion of aromatic ketones to arenecarboxylic esters via carbon-carbon bond-cleavage reactions

Aromatic methyl ketones, ss-keto esters, and trifluoromethyl-l,3- diketones can be directly converted to arene-carboxylic esters via carbon-carbon bond cleavage of pyridinium iodide intermediates in the presence of copper(II) oxide, iodine, pyridine, and potassium carbonate in alcoholic media. The advantages of the present method in terms of good yields, mild reaction conditions, and inexpensive reagents should make this protocol a valuable alternative to the existing methods.

MORPHOLINE COMPOUND

A compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof have affinity for CCR3, and can be pharmaceutical products for the treatment and/or prophylaxis of immune or inflammatory diseases.

CaSR ANTAGONIST

The present invention provides a compound having a calcium-sensitive receptor antagonistic action, a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis. A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: wherein each symbol is as defined in the description.

Novel acyl hydrazino thiophene derivatives, process for preparing them, their use as medicinal products, pharmaceutical compositions and novel use

The invention concerns novel compounds of formula (I), process for making, pharmaceutical compositions and methods of treating diseases associated with abnormal physiological behavior in the secretion and/or the activity of cysteine proteases especially c

A simple and facile carboxylation method and its application for synthesis of liquid crystals

Sonication of a mixture of magnesium powder, 1,2-dibromoethane, aryl bromide and diethyl dicarbonate in THF followed by treatment with BF 3·OEt2 at room temperature afforded aryl ester with reasonable yield. A series of aryl bromides were investigated and transformed to their corresponding aryl esters under the reaction conditions.